These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 30332685)

  • 1. Chemical hazard prediction and hypothesis testing using quantitative adverse outcome pathways.
    Perkins EJ; Gayen K; Shoemaker JE; Antczak P; Burgoon L; Falciani F; Gutsell S; Hodges G; Kienzler A; Knapen D; McBride M; Willett C; Doyle FJ; Garcia-Reyero N
    ALTEX; 2019; 36(1):91-102. PubMed ID: 30332685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Building and Applying Quantitative Adverse Outcome Pathway Models for Chemical Hazard and Risk Assessment.
    Perkins EJ; Ashauer R; Burgoon L; Conolly R; Landesmann B; Mackay C; Murphy CA; Pollesch N; Wheeler JR; Zupanic A; Scholz S
    Environ Toxicol Chem; 2019 Sep; 38(9):1850-1865. PubMed ID: 31127958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Challenge for Adverse Outcome Pathway (AOP)-based Chemical Safety Assessment].
    Yamada T; Ashikaga T; Kojima H; Hirose A
    Yakugaku Zasshi; 2020; 140(4):481-484. PubMed ID: 32238628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA).
    Tollefsen KE; Scholz S; Cronin MT; Edwards SW; de Knecht J; Crofton K; Garcia-Reyero N; Hartung T; Worth A; Patlewicz G
    Regul Toxicol Pharmacol; 2014 Dec; 70(3):629-40. PubMed ID: 25261300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When Are Adverse Outcome Pathways and Associated Assays "Fit for Purpose" for Regulatory Decision-Making and Management of Chemicals?
    Coady K; Browne P; Embry M; Hill T; Leinala E; Steeger T; Maślankiewicz L; Hutchinson T
    Integr Environ Assess Manag; 2019 Jul; 15(4):633-647. PubMed ID: 30908812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The adverse outcome pathway concept: A basis for developing regulatory decision-making tools.
    Delrue N; Sachana M; Sakuratani Y; Gourmelon A; Leinala E; Diderich R
    Altern Lab Anim; 2016 Oct; 44(5):417-429. PubMed ID: 27805824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AOPERA: A proposed methodology and inventory of effective tools to link chemicals to adverse outcome pathways.
    Rycroft TE; Foran CM; Thrash A; Cegan JC; Zollinger R; Linkov I; Perkins EJ; Garcia-Reyero N
    ALTEX; 2020; 37(1):64-74. PubMed ID: 31453632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AOP-DB: A database resource for the exploration of Adverse Outcome Pathways through integrated association networks.
    Pittman ME; Edwards SW; Ives C; Mortensen HM
    Toxicol Appl Pharmacol; 2018 Mar; 343():71-83. PubMed ID: 29454060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale.
    Halappanavar S; van den Brule S; Nymark P; Gaté L; Seidel C; Valentino S; Zhernovkov V; Høgh Danielsen P; De Vizcaya A; Wolff H; Stöger T; Boyadziev A; Poulsen SS; Sørli JB; Vogel U
    Part Fibre Toxicol; 2020 May; 17(1):16. PubMed ID: 32450889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse outcome pathway development from protein alkylation to liver fibrosis.
    Horvat T; Landesmann B; Lostia A; Vinken M; Munn S; Whelan M
    Arch Toxicol; 2017 Apr; 91(4):1523-1543. PubMed ID: 27542122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse outcome pathways during early fish development: a conceptual framework for identification of chemical screening and prioritization strategies.
    Volz DC; Belanger S; Embry M; Padilla S; Sanderson H; Schirmer K; Scholz S; Villeneuve D
    Toxicol Sci; 2011 Oct; 123(2):349-58. PubMed ID: 21750347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
    Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
    Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing the adverse outcome pathway framework-An international horizon scanning approach.
    LaLone CA; Ankley GT; Belanger SE; Embry MR; Hodges G; Knapen D; Munn S; Perkins EJ; Rudd MA; Villeneuve DL; Whelan M; Willett C; Zhang X; Hecker M
    Environ Toxicol Chem; 2017 Jun; 36(6):1411-1421. PubMed ID: 28543973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How Adverse Outcome Pathways Can Aid the Development and Use of Computational Prediction Models for Regulatory Toxicology.
    Wittwehr C; Aladjov H; Ankley G; Byrne HJ; de Knecht J; Heinzle E; Klambauer G; Landesmann B; Luijten M; MacKay C; Maxwell G; Meek ME; Paini A; Perkins E; Sobanski T; Villeneuve D; Waters KM; Whelan M
    Toxicol Sci; 2017 Feb; 155(2):326-336. PubMed ID: 27994170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Outcome Pathways as Tools to Assess Drug-Induced Toxicity.
    Vinken M
    Methods Mol Biol; 2016; 1425():325-37. PubMed ID: 27311472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond chemicals: Opportunities and challenges of integrating non-chemical stressors in adverse outcome pathways.
    Clerbaux LA; Filipovska J; Nymark P; Chauhan V; Sewald K; Alb M; Sachana M; Beronius A; Amorim MJ; Wittwehr C
    ALTEX; 2024; 41(2):233-247. PubMed ID: 37980615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse Outcome Pathways can drive non-animal approaches for safety assessment.
    Burden N; Sewell F; Andersen ME; Boobis A; Chipman JK; Cronin MT; Hutchinson TH; Kimber I; Whelan M
    J Appl Toxicol; 2015 Sep; 35(9):971-5. PubMed ID: 25943792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated Approaches to Testing and Assessment: OECD Activities on the Development and Use of Adverse Outcome Pathways and Case Studies.
    Sakuratani Y; Horie M; Leinala E
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():20-28. PubMed ID: 29316278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linking Mitochondrial Dysfunction to Organismal and Population Health in the Context of Environmental Pollutants: Progress and Considerations for Mitochondrial Adverse Outcome Pathways.
    Dreier DA; Mello DF; Meyer JN; Martyniuk CJ
    Environ Toxicol Chem; 2019 Aug; 38(8):1625-1634. PubMed ID: 31034624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiating Pathway-Specific From Nonspecific Effects in High-Throughput Toxicity Data: A Foundation for Prioritizing Adverse Outcome Pathway Development.
    Fay KA; Villeneuve DL; Swintek J; Edwards SW; Nelms MD; Blackwell BR; Ankley GT
    Toxicol Sci; 2018 Jun; 163(2):500-515. PubMed ID: 29529260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.